Roche Pharmaceutical Development and Sales Overview

Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Phase/study # of patients Design Primary endpoint Status CT Identifier " ARM A: Lunsumio plus Polivy ARM B: R + GemOx Progression-free survival FPI Q2 2022 DLBCL-diffuse large B cell lymphoma; SCT=stem cell transplant; R=Rituxan/MabThera; GemOx-Gemcitabin und Oxaliplatin 2L+ SCT ineligible DLBCL Phase III SUNMO N=222 NCT05171647 Roche 83 83 Oncology

View entire presentation